 

Active ingredient: Baclofen 

 

Form/Route: Orally Disintegrating Tablets/ Oral 

 

Recommended studies: 1 study 

 

Type of study: Fasting 

Design: single-dose, two-way crossover in-vivo 

Strength: 20 mg 

Subjects: Normal healthy males and females, general population. 

 Additional Comments: Females should not be pregnant, and if applicable, should practice 
abstention or contraception during the study. 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Baclofen in plasma 

 

Bioequivalence based on (90% CI): Baclofen 

 

Waiver request of in-vivo testing: 10 mg based on (1) acceptable bioequivalence study on the 
20 mg strength, and (ii) proportional similarity in the formulations and (ii) acceptable in vitro 
dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


